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PPAR-γ and aging:  
one link through klotho?
Ruihua Zhang1 and Feng Zheng1
PPAR-γ, a transcription factor involved in adipogenesis, glucose 
homeostasis, bone turnover, and inflammation, has now been shown to 
increase klotho expression. Klotho is predominantly expressed by the 
kidney and functions at the tubule and in the circulation as an anti-aging 
factor and a hormone participating in mineral metabolism. The finding 
that klotho is upregulated by PPAR-γ may prompt further exploration of 
the role and mechanism of action of PPAR-γ  in aging and bone diseases.
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Aging is an inevitable but an extendable 
process. Both exogenous and endogenous 
factors may change the course of 
biological aging. For instance, calorie 
restriction has been consistently shown 
to prolong life span, from lower organ-
isms to primates. Additionally, mutation, 
deletion, or overexpression of evolution-
arily conserved molecules involved in 
the growth hormone/insulin/insulin-like 
growth factor-1 (IGF-1) signaling path-
way alters the aging process.1
Oxidative stress, caused by an imbalance 
between oxidant production and antioxi-
dants, is widely believed to be a central 
player in aging. While the production of 
reactive free radicals is absolutely required 
for host defenses and normal cell functions, 
the presence of detoxificants, including 
superoxide dismutase, catalase, glutathione 
peroxidase, and glutathione reductase, 
is critical in maintaining a normal redox 
state and in cell life-and-death decisions 
during stress. It is known, for example, that 
the prosurvival action of nuclear factor-κB 
is partly mediated by its increasing of the 
transcription of super oxide dismutase and 
catalase. The upregulation of antioxidants 
also contributes to the anti-aging function 
of the forkhead box O (FOXO) family of 
transcription factors. As mice transgenic 
for antioxidant molecules such as catalase 
and thioredoxin have an increased life 
span, and mice deficient in methionine sul-
foxide reductase, an antioxidation enzyme, 
have a decreased life span, these data sup-
port the important role of antioxidants in 
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aging.2 Aging is commonly associated with 
excessive oxidant production due partly to 
mitochondrial dysfunction. Mitochondria 
as the power plants for cells are a major 
source of reactive oxygen species (ROS). 
During the process of ATP generation, 
ROS are a by-product generated by com-
plex I and III in the electron transport 
chain. The function of mitochondria is 
progressively decreased in aging because 
of the accumulation of mitochondrial 
DNA mutation and decreased activity of 
enzymes and components of the electron 
transport chain. It is unknown, however, 
how ROS generation can be dispropor-
tionately increased when energy produc-
tion is decreased in aging. One model may 
be that electron stalling, due partly to the 
rate of electron entry into complex I and 
III, exceeds the rate of transition in the 
transport chain, the end result being ROS 
accumulation.3 The findings that calorie 
restriction reduces ROS generation while 
increasing mitochondrial number and 
respiration rate indirectly support this 
model. Interestingly, early aging occurs 
in mitochondrial DNA proofread-
ing polymerase-γ knockout mice in the 
absence of obvious oxidative stress. As 
patients with mitochondrial genetic dis-
eases also display early-aging phenotypes, 
the integrity of mitochondria may be an 
independent risk factor for aging. The 
findings that knockout of two of the DNA 
damage repair genes causes premature 
aging in the presence of increased anti-
oxidants and decreased ROS production 
in mice4 further suggest that molecular 
pathways other than free radical damage 
are involved in aging.
Klotho is a newly identified anti-aging 
factor that is not directly involved in 
regulation of redox state and is not evo-
lutionarily conserved.5 The klotho gene 
encodes a single-pass transmembrane 
protein with a long extracellular domain 
(two internal repeats, ~900 amino acids) 
and a short cytoplasmic tail (10 amino 
acids). The extracellular domain of klotho 
shares homology to mammalian lactose-
phlorizin hydrolase and β-glucosidase 
in bacteria and plants. Klotho exists in 
both secreted and membranous forms. 
Secreted forms are derived both from the 
shedding of extracellular domain and as 
a product of alternative splicing. Klotho 
is expressed predominantly in renal distal 
convoluted tubules and in choroid plexus 
in the brain. The anti-aging function of 
klotho has been studied in transgenic 
mice. Klotho-deficient mice develop a 
premature-aging phenotype that includes 
a drastically shortened life span, skin and 
muscle atrophy, osteoporosis, pulmonary 
emphysema, and extensive ectopic calci-
fication.5 In contrast, mice transgenic 
for klotho exhibit an extended life span.6 
More interestingly, Arking et al. reported 
that a functional variant of klotho in 
humans is associated with increased lon-
gevity.7 One variant with a substitution 
of position 352 phenylalanine with valine 
resulted in a sixfold decrease in secreted 
klotho levels. Furthermore, this substi-
tution may eliminate the β-glucosidase 
activity of klotho. Surprisingly, the 352 
phenylalanine homozygote did not show 
increased longevity and instead had lower 
survival advantage over the 352 phenyla-
lanine-to-valine variant heterozygote.
Inhibition of the insulin/IGF-1 signaling 
pathway and ROS may contribute to the 
anti-aging function of klotho.5 Whereas 
klotho-deficient mice are hypoglycemic 
and demonstrate hypersensitivity to insu-
lin, overexpressing mice have elevated 
fasting insulin levels with glucose intol-
erance. The addition of klotho to L6 cells 
in vitro decreases both insulin and IGF-1
–stimulated insulin receptor and insulin 
receptor substrate 1 and 2 phosphoryla-
tion and phosphatidylinositol-3′-kinase 
and Akt/protein kinase B activation. 
Moreover, the administration of klotho to 
normal mice results in decreased glucose 
and insulin tolerance. These data support 
the involvement of klotho in the insulin/
IGF-1 pathway. As klotho transgenic 
mice are resistant to paraquat, a robust 
ROS generator that induces animal death, 
klotho may prolong life span through the 
inhibition of oxidative stress. The activa-
tion of FOXOs and superoxide dismutase 
2 has been implicated in the anti-ROS 
effect of klotho.
The data are not completely clear, how-
ever, regarding the anti-aging function 
of klotho, since it is critically involved 
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figure 1 | A putative role of PPAR-γ  in aging. PPAR-γ increases klotho and decreases inflammation, 
which may increase life span. It is unknown whether the improvement of insulin sensitivity by PPAR-γ 
is beneficial or harmful. As PPAR-γ  activation may increase the risk of cardiovascular disease and 
decrease the capability of bone remodeling, a series of well-planned, careful studies in aging models 
is required to determine the effect of PPAR-γ activation and inhibition on the aging process. FOXOs, 
forkhead box O transcription factors; ROS, reactive oxygen species; PKB, protein kinase B.
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in phosphate homeostasis and vitamin 
D metabolism. A patient with transloca-
tion in a breakpoint adjacent to klotho 
developed hypophosphatemic rickets and 
hyperparathyroidism in the presence of 
elevated klotho.8 Mice deficient in klotho 
have elevated plasma calcium, phosphate, 
and 1,25(OH)2D3 levels. Restriction of 
dietary phosphorus or vitamin D corrects 
the early-aging phenotype and prolongs 
the life span of klotho-deficient mice. 
The regulation of phosphate by klotho is 
probably mediated by its interaction with 
fibroblast growth factor-23 (FGF-23), a 
30-kilodalton secreted protein that acts as 
a key regulator in phosphate homeostasis. 
FGF-23 decreases intestinal and kidney 
phosphate absorption. In the absence of 
klotho, however, FGF-23 does not bind 
efficiently to its receptor to induce intra-
cellular signaling. This is more obvious 
in klotho-deficient mice, as these mice 
have hyperphosphatemia in the pres-
ence of a nearly 1,200-fold increase in 
serum FGF-23. Interestingly, FGF-23 
knockout mice exhibit a nearly identical 
early-aging phenotype.9 The defect could 
largely be corrected after crossing of FGF-
23-null mice with 1α(OH)ase-null mice 
to diminish the activity of 1,25(OH)2D3. 
The status of phosphate homeostasis in 
klotho-overexpressing mice is not clear.
The presence of hypercalcemia in klot-
ho-deficient mice suggests that klotho 
may also be involved in calcium home-
ostasis. In the kidney, klotho is coex-
pressed with TRPV5, a calcium channel 
transient receptor that is responsible for 
calcium reabsorption in distal convo-
luted tubular cells. Klotho increases the 
number of TRPV5 on cell membranes 
and thus the influx of calcium through its 
glucu ronidase-like activity that hydrolyzes 
N-linked oligo saccharides in TRPV5. In 
addition to its function as a calcium influx 
channel in the kidney, TRPV5 also plays 
a role in osteoclastic activity. TRPV5 is 
expressed by osteoclasts. Mice lacking 
TRPV5 have decreased bone resorp-
tion due partly to the dysfunction of 
osteoclasts. As mice lacking klotho have 
a more severe bone phenotype, klotho 
may also affect normal bone turnover via 
the regulation of phosphate and calcium 
homeostasis, vitamin D metabolism, and 
osteoclast function.
The expression of klotho is reduced in 
aging, chronic renal failure, type 2 diabe-
tes, and acute ischemic injury. Further-
more, both angiotensin II and oxidative 
stress decrease klotho expression. The 
underlying molecular mechanisms for 
the regulation of klotho expression are 
not clear. Zhang et al.10 (this issue) report 
that peroxisome proliferator-activated 
receptor-γ (PPAR-γ) increases renal tubu-
lar klotho mRNA and protein expression 
in vitro and in vivo. More importantly, 
they were able to locate two non-ca-
nonical PPAR-γ binding sites upstream 
of the klotho gene and clearly demon-
strated that these sites are important for 
the regulation of klotho expression by 
PPAR-γ. Given that PPAR-γ itself func-
tions as a critical regulator of glucose 
and lipid metabolism and may play an 
important role in anti-inflammation,11 
this finding of an increase in klotho by 
PPAR-γ may help to generate interest in 
further examining the role of PPAR-γ 
in aging.
Aging is commonly associated with 
the metabolic syndrome, characterized 
by insulin resistance, obesity, dyslipi-
demia, abnormal glucose metabolism, 
and hypertension. Forty per cent of the 
United States population over 40 years 
old has the metabolic syndrome, which 
carries an increased risk for cardiovas-
cular diseases. Because the activation 
of PPAR-γ by agonists such as thiazoli-
dinediones improves insulin resistance, 
hyperlipidemia, and glycemic levels, it 
constitutes an important part of therapy 
for the metabolic syndrome. This theo-
retically would help to increase longevity, 
even though it may not directly affect the 
process of biological aging.
Additionally, aging is commonly asso-
ciated with low-grade chronic inflamma-
tion. As PPAR-γ has long been known 
as an anti-inflammatory molecule that 
suppresses nuclear factor-κB, AP-1, 
and STAT and decreases production of 
cytokines and chemokines, this effect of 
PPAR-γ may be an added benefit in the 
modulation of aging (Figure 1).
However, the activation of PPAR-γ 
is associated with increased adipocyte 
differentiation that promotes obesity and 
weight gain. Specifically in bone marrow, 
PPAR-γ suppresses the differentiation of 
mesenchymal progenitors to osteob-
lasts while steering progenitors in the 
direction of more adipocyte generation, 
which results in decreased osteoblas-
togenesis and bone remodeling. This 
raises concern about whether the use of 
thiazolidinediones as PPAR-γ agonists 
may increase the risk of bone fracture 
in aging. Interestingly, the increase of 
klotho by PPAR-γ may partly offset this 
adverse effect, because klotho facili-
tates bone mineralization and increases 
TRPV5 in osteoclasts. The major con-
cern, however, is about the latest report 
of increasing mortality in type 2 diabetic 
patients treated by the PPAR-γ agonists 
rosiglitazone and pioglitazone. Because 
of this safety-versus-efficacy issue, one 
should be cautious regarding the ben-
efit of PPAR-γ activation for aging, even 
though it increases klotho.
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